Skip to Main Content


Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of purchasers of TG Therapeutics, Inc. (NASDAQ: TGTX) (“TG Therapeutics”) securities.

On August 1, 2023, TG Therapeutics announced its financial results for the second quarter and reported a net loss of $47.6 million and $86.8 million for the three and six months ended June 30, 2023, compared to $40.5 million and $109.5 million for the three and six months ended June 30, 2022. Additionally, TG Therapeutics revealed that its highly anticipated multiple sclerosis drug, “Briumvi,” which launched in the U.S. in late January, missed analysts' consensus expectations of nearly $17.5 million, generating only $16.1 million in U.S. drug sales.

Following this news, the price of TG Therapeutics’ stock declined by nearly 50%, to close at $10.49 per share on August 1, 2023. 

If you have any questions or would like to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP:  Jonathan Naji, Esq. (484) 270-1453 or via e-mail at  

* Denotes required field
# of Shares
Price per Share
Principal Amount
Amount Paid
Series or CUSIP
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of TG Therapeutics, Inc. prior to the Class Period?
Are you a current or former employee of TG Therapeutics, Inc.?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC disclaimer
I would like to receive new case alerts by email